SurgiVance

Executive Summary

SurgiVance is a Boston-based medical device company founded in 2018, pioneering a direct-to-digital pathology platform designed to transform cancer diagnostics. Traditional pathology workflows are slow and centralized, often requiring days for results. SurgiVance's integrated system—a tabletop imager, AI-powered software, and disposable cassettes—enables rapid, high-resolution digital imaging at the point of care. This on-site approach aims to accelerate diagnosis, reduce errors, and improve patient outcomes in cancer care. The platform's scalability and cost-effectiveness position it to disrupt the $5B+ digital pathology market, especially in outpatient and community settings where access to pathology expertise is limited. SurgiVance has yet to disclose funding rounds or commercial milestones, but its novel technology has the potential to address critical bottlenecks in oncology. The company's focus on FDA-cleared digital pathology aligns with growing regulatory acceptance and reimbursement trends. With a seasoned team likely leveraging Boston's medtech ecosystem, SurgiVance is poised for significant traction. Key near-term milestones include regulatory submissions, clinical validations, and strategic partnerships. Given the high unmet need and early-stage innovation, SurgiVance represents a promising, albeit speculative, opportunity in digital pathology.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for the tabletop digital imager and cassette system70% success
• Q3 2026Initiation of a pivotal clinical study for the AI diagnostic software60% success
• Q3 2026Series A funding round or strategic partnership with a diagnostic company80% success